Your doctor might give you a different kind of medicine to overcome the side effects. No data are available for ibandronate. The most commonly used antiresorptive drugs belong to a class of compounds referred to as bisphosphonates, also called diphosphonates. Health tools for patients and caregivers, provided by the Endocrine Society.

All rights reserved. There is abundant evidence suggesting that bisphosphonates decrease bone resorption by inhibiting the function of osteoclastsIn conditions of osteoporosis (bone density z-score greater than 2.5 standard deviations below the mean on DEXA scanning) and other diseases in which there is excessive bone resorption as described, bisphosphonate therapy is instituted to prevent fractures. But perhaps you have questions about your therapy. Overall, when you take this type of medicine, your chance of preventing fractures is high, and the risk of serious problems is low.Find an endocrinologist today to ensure that you are on the path to health with the right medical care. There are no data for ibandronate.The extensions of alendronate from the Fracture Intervention Trial (FIT) and zoledronic acid were of similar design. As you age — especially after menopause — bones break down more quickly. Several studies have confirmed that bisphosphonates may decrease the risk of sustaining an insufficiency fracture. While there is limited direct evidence to support screening for osteoporosis to reduce fracture risk, DEXA is recommended for women aged 65 years and older because of strong evidence that bisphosphonates significantly reduce hip-fracture risk for older women who have met the … Compston and Bilezikian suggest reassessment after one year for risedronate, one to two years for alendronate, and two to three years for zoledronic acid.9 A "holiday" implies that treatment will be restarted after some time off. It takes several months for bisphosphonates to work. New data for zolendronic acid demonstrate a sustained effect beyond that of alendronate since bone turnover markers did not change for three years after six years of therapy.5 Data for risedronate suggest a faster resolution or effect of one to two years. Although this article focuses on long-term treatment of osteoporosis, the fact is that many older people at high risk of fracture receive no treatment, and even when prescribed, patients' nonadherence with drug therapy is widespread. Effect of stopping risedronate after long-term treatment on bone turnover. The risk of vertebral, hip, and other nonvertebral fractures was reduced in women with osteoporosis. This injury, known as atypical femoral fracture, can cause pain in the thigh or groin that begins subtly and may gradually worsen. The registration trials for bisphosphonates were three or four years in duration, with fractures assessed as the primary end point. Get answers to some of the most common questions about osteoporosis treatment.If you're undergoing osteoporosis treatment, you're taking a step in the right direction for your bone health. Because bone rebuilding cannot keep pace, bones deteriorate and become weaker.Most osteoporosis medications work by reducing the rate at which your bones break down. Because of the increasing use of bisphosphonates to improve bone density in postmenopausal osteoporosis, physicians are now encountering a large number of patients with fractures who have received bisphosphonate treatment prior to their fractures. Clinical trials have found that these drugs, unlike the hormone therapy tamoxifen, increase bone fracture risk. Don't put anything else into your stomach for 30 to 60 minutes, after which you can eat, drink other liquids and take other medications.Intravenous forms of bisphosphonates, such as ibandronate and zoledronic acid, don't cause stomach upset. The mean serum levels of bone turnover markers measured remained within the premenopausal reference range in both groups. You should read the product information to ensure you are current with the latest edition.Remember, continued therapy does not mean bisphosphonates are the only option. Those who were no longer taking alendronate showed a gradual rise in markers over five years.